17:48 , Mar 28, 2019 |  BC Innovations  |  Translation in Brief

Tuning metabolism in liver organoids

An Alnylam-MIT collaboration has used RNAi technology to tune enzyme expression in hepatocyte-based organoids to better model drug metabolism during tox screens. The collaboration with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) built on a series of papers...
01:10 , Aug 11, 2017 |  BC Innovations  |  Strategy

The flip-side of immunotherapy

In the smaller print of last week’s deal between IFM Therapeutics Inc. and Bristol-Myers Squibb Co. was the latest example of a growing trend of companies aiming to draw extra value out of a cancer...
23:11 , Feb 24, 2017 |  BioCentury  |  Product Development

Dendritic cell control

Denceptor Therapeutics Ltd. is developing a technology for inducing antigen-specific T cell responses that the company believes will be more efficacious than other dendritic cell-targeted approaches for cancer while avoiding the safety issues raised by...
07:00 , Mar 24, 2016 |  BC Innovations  |  Product R&D

Liver-bound

Ionis Pharmaceuticals Inc. is retooling its antisense technology with a sugar-based conjugate that boosts uptake into liver cells. By tapping the power of GalNAc sugars to latch onto hepatocyte receptors, the company believes it can...
07:00 , Mar 24, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Enhancing hepatocyte uptake of antisense oligonucleotides (ASOs) via conjugation to N-acetylgalactosamine (GalNAc) clusters targeting asialoglycopro

Drug delivery TECHNOLOGY: Other Conjugating ASOs to GalNAc clusters targeting ASGR1 could help improve hepatocyte uptake of antisense therapeutics. The GalNAc cluster consisted of a tris(hydroxymethyl)aminomethane scaffold containing a linker that could be conjugated to...
07:00 , Oct 16, 2014 |  BC Innovations  |  Targets & Mechanisms

Alnylam interrupts preeclampsia

Preeclampsia often involves overactivation of the renin-angiotensin system that regulates blood pressure, but inhibiting the pathway is not possible because it would be toxic to the fetus. Alnylam Pharmaceuticals Inc. has developed an siRNA conjugate...
07:00 , Jul 24, 2014 |  BC Innovations  |  Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....
07:00 , Oct 24, 2013 |  BC Innovations  |  Cover Story

A platform for RNA

An information explosion on the number of functional RNA molecules expressed in cells and the mechanisms by which they control gene expression 1,2 is driving the formation and funding of biotechs developing oligonucleotide-based therapeutics. Pharmas...
07:00 , Oct 1, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Hematology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hematology Transfusion Asialoglycoprotein receptor 1 (ASGR1); ASGR2 A study in mice and in cell culture suggests that inhibitors of ASGR1 and ASGR2 could help improve platelet...